Notification regarding the change of significant holding
Pursuant to Article 147 of Market in Financial Instruments Act (Official Gazette of the Republic of Slovenia No. 77/2018, as amended, "ZTFI-1"), in conjunction with Article 140(2) of ZTFI-1, Lek Pharmaceuticals d.d., Verovškova ulica 57, 1526 Ljubljana ("Lek" or "Company"), hereby publishes the following notice:
On 2 August 2023, the Company, as the issuer of shares with the code NVRR, received 2 notifications regarding the change of significant holding in accordance with ZTFI-1 and Decision on information on significant holdings (Official Gazette of the Republic of Slovenia No. 30/19, the "Decision"), namely from Novartis Pharma AG, a company limited by shares (Aktiengesellschaft), incorporated under the laws of Switzerland and registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland, under registration number CHE 106.052.527, with registered office at Lichtstrasse 35, 4056 Basel, Switzerland ("Novartis Pharma AG") and Sandoz AG, a company limited by shares (Aktiengesellschaft), incorporated under the laws of Switzerland and registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland, under registration number CHE 103. 977.765, with registered office at Lichtstrasse 35, 4056, Switzerland ("Sandoz AG"). It follows from the notifications that on 27 July 2023, Novartis Pharma AG and Sandoz AG entered into an agreement on the sale of shares, whereby they agreed on the sale and transfer of 1,933,176 shares with the code NVRR, which represents 100.00% of the voting rights in the Company, and that on the same day the Company's shares (and thus also the voting rights) were transferred to Sandoz AG.
Copies of both notifications are attached to this notice.